The investment firm co-led a $125 million Series A round for Ambros Therapeutics, a Vivek Ramaswamy co-founded company with a medicine nearing pivotal testing.
Jacob Bell is a Senior Reporter at BioPharma Dive. He specializes in covering themes related to medicine and healthcare, pharmaceuticals, and sports, with a focus on topics such as pharmaceutical manufacturing, regulation, and competitive sports. Jacob's work has been featured in notable publications including BioPharma Dive, PharmaVoice, and Yahoo Finance.